Heerma Peter — SEC insider filings
SEC reporting owner CIK 1789617. 28 insider filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 28 filings on record, filed 2020-10-05 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 35 legs across 25 filings — 359,908 shares, $19,896,879 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 42.
- Largest priced transaction: sale of 93,604 shares @ $63.25 ($5,920,182) in Travere Therapeutics, Inc., filed 2026-09-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | EVP, CHIEF COMMERCIAL OFFICER | 28 | — | 35 legs · 359,908 sh · $19,896,879 | 42 |
Insider filings — Heerma Peter
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 39,283 @ $26.88 · Option exercise (M): 1,381 @ $22.40 · Option exercise (M): 36,526 @ $8.93 · Sale (S): 71,938 @ $62.05 · Sale (S): 27,421 @ $62.59 · Sale (S): 1,400 @ $63.65 · +15 more | EDGAR |
| 2026-05-06 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 4,250 @ $0 · Sale (S): 2,174 @ $46.65 · Grant/award (A): 8,500 (derivative) @ $0 · Option exercise (M): 4,250 (derivative) @ $0 | EDGAR |
| 2026-04-15 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 14,000 @ $0 · Sale (S): 7,215 @ $41.93 | EDGAR |
| 2026-02-03 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 26,120 @ $0 · Sale (S): 7,310 @ $32.12 · Grant/award (A): 69,640 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 4,980 @ $40 | EDGAR |
| 2025-11-04 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 5,591 @ $35 · Gift (G): 1,078 @ $0 | EDGAR |
| 2025-10-30 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 2,662 @ $30 | EDGAR |
| 2025-09-24 | 4 | Travere Therapeutics, Inc. (TVTX) | Gift (G): 891 @ $0 | EDGAR |
| 2025-05-05 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 4,920 · Sale (S): 1,771 @ $21.05 · Option exercise (M): 4,920 (derivative) @ $0 | EDGAR |
| 2025-02-12 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 8,000 · Sale (S): 3,074 @ $25 · Sale (S): 2,568 @ $23.53 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 21,500 @ $0 · Sale (S): 5,166 @ $20.12 · Grant/award (A): 58,000 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 1,584 @ $18.94 | EDGAR |
| 2024-09-09 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,750 @ $0 · Sale (S): 2,191 @ $11.52 | EDGAR |
| 2024-02-02 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 25,000 @ $0 · Sale (S): 4,195 @ $8.53 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2024-01-25 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 1,559 @ $9.07 | EDGAR |
| 2023-10-04 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 3,091 @ $8.25 | EDGAR |
| 2023-02-02 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 20,250 @ $0 · Sale (S): 1,779 @ $21.75 · Grant/award (A): 54,500 (derivative) @ $0 · Grant/award (A): 6,750 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 1,550 @ $21.90 | EDGAR |
| 2022-10-06 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 3,042 @ $25.68 | EDGAR |
| 2022-02-02 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 9,840 @ $0 · Sale (S): 1,125 @ $27.40 · Grant/award (A): 39,360 (derivative) @ $0 · Grant/award (A): 9,840 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2022-01-26 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 1,875 @ $24.98 | EDGAR |
| 2021-10-05 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 3,058 @ $24.77 | EDGAR |
| 2021-08-17 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 4,500 @ $0 · Sale (S): 1,407 @ $17.12 | EDGAR |
| 2021-02-09 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 1,125 @ $31.41 · Sale (S): 1,125 @ $31.58 | EDGAR |
| 2021-02-05 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 4,500 @ $0 | EDGAR |
| 2021-02-03 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 563 @ $30.75 · Sale (S): 563 @ $28.91 | EDGAR |
| 2021-01-25 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 15,000 @ $0 · Grant/award (A): 57,500 (derivative) @ $0 | EDGAR |
| 2020-10-05 | 4 | Retrophin, Inc. (RTRX) | Sale (S): 2,188 @ $18.90 · Sale (S): 2,188 @ $19.35 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1789617 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs